Medtronic gets FDA approval for new heart-condition treatment

Medtronic
MDT,
+2.27%
said the U.S. Food and Drug Administration has approved its PulseSelect Pulsed Field Ablation System for the treatment of two heart conditions.

The Dublin-based medical technology company on Wednesday said the company’s heart technology can now treat paroxysmal and persistent atrial fibrillation following the FDA’s approval.